OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
Ni Zeng, Jiaqi Han, Zijian Liu, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3386-3386
Open Access | Times Cited: 5
Ni Zeng, Jiaqi Han, Zijian Liu, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3386-3386
Open Access | Times Cited: 5
Showing 5 citing articles:
CDK4/6 as a Therapeutic Target in HR+/HER2− Breast Cancer Cells—Current Treatment Status
Katherine Krupa, Anna Liszcz-Tymoszuk, Natalia Czerw, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 1039-1039
Open Access
Katherine Krupa, Anna Liszcz-Tymoszuk, Natalia Czerw, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 1039-1039
Open Access
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study
L. Provenzano, M.V. Dieci, G. Curigliano, et al.
Annals of Oncology (2025)
Closed Access
L. Provenzano, M.V. Dieci, G. Curigliano, et al.
Annals of Oncology (2025)
Closed Access
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer
Juan Hong, Tujia Chen, Ouyang Lihui, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 4, pp. 559-566
Open Access
Juan Hong, Tujia Chen, Ouyang Lihui, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 4, pp. 559-566
Open Access
Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
N. А. Avxentyev, I. I. Andreyashkina, Е. В. Артамонова, et al.
Tumors of female reproductive system (2024) Vol. 20, Iss. 1, pp. 64-81
Open Access
N. А. Avxentyev, I. I. Andreyashkina, Е. В. Артамонова, et al.
Tumors of female reproductive system (2024) Vol. 20, Iss. 1, pp. 64-81
Open Access
Cost-effectiveness comparison of dalpiciclib and abemaciclib Combined with an aromatase inhibitor as first-line treatment for HR+/ HER2− advanced breast cancer
Juan Hong, Tujia Chen, Jun Meng, et al.
Research Square (Research Square) (2023)
Open Access
Juan Hong, Tujia Chen, Jun Meng, et al.
Research Square (Research Square) (2023)
Open Access
